Skip to main content
SpringerLink
Log in

Isotretinoin Use and Compliance with the Dutch Pregnancy Prevention Programme

A Retrospective Cohort Study in Females of Reproductive Age Using Pharmacy Dispensing Data

  • Original Research Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Background: Isotretinoin is very effective in the treatment of severe acne. However, because of the teratogenic properties of this agent an isotretinoin Pregnancy Prevention Programme (PPP) was implemented in the Netherlands to guarantee that treatment is contraindicated in women of reproductive age unless at least one effective method of contraception is used. Furthermore, the PPP stipulates that isotretinoin treatment should be managed by physicians or specialists experienced in treatment with this drug and that only monthly prescriptions are issued.

Objective: To assess compliance with the Dutch isotretinoin PPP in women of reproductive age during the study period of 1 January 2005 to 31 December 2008.

Methods: Detailed information on dispensed medication and co-medication was available from the Dutch Foundation of Pharmaceutical Statistics. Four types of outcome were studied: concomitant dispensing of hormonal contraceptive with isotretinoin; the proportion of specialist prescribing of isotretinoin; prescribing of conventional acne therapy prior to isotretinoin initiation; and isotretinoin dispensing exceeding the maximum amount. The use of contraceptives in women aged between 15 and 45 years was defined as concomitant if the period of systemic contraceptive use overlapped the period of isotretinoin dispensing for at least 10 days, or if any dispensing of an intrauterine or intravaginal contraceptive was recorded since the year 2000. Dispensings were separated into those prescribed by either specialists or general practitioners (GPs). The use of antibacterials, anti-androgens or topical agents against acne was checked 4 months prior to an isotretinoin dispensing, and a possible excess of the maximum amount of isotretinoin was defined as prescriptions of more than 100 defined daily doses.

Results: During the study period, data were available for 442 Dutch pharmacies encompassing 4881 women of reproductive age using isotretinoin at least once during study period. Among women of reproductive age, the use of isotretinoin increased during the study period. The proportion of isotretinoin initiation with concomitant oral hormonal or intrauterine contraceptives was low (59.3% [95% CI 57.6, 61.0]). Initiation of isotretinoin by a specialist increased the chance for concomitant contraception by 26% (95% CI 6.0, 49.0); in 78.2% (95% CI 76.8, 79.6) of women, isotretinoin was initiated by a specialist. Conventional acne therapy up to 16 months prior to isotretinoin initiation was found in 70% of the women (70.3% [95% CI 66.0, 74.6]). In 1.4% (95% CI 1.0, 1.8) of cases of treatment initiation, the amount of isotretinoin dispensed on one prescription seemed too high.

Conclusion: Attention should be paid to improving the implementation of the isotretinoin PPP. Despite clear guidelines and warnings in the product information, our study strongly suggests that concomitant use of isotretinoin and contraceptives is too low. Even though we will have missed non-pharmacological forms of contraception, these results raise doubts about the safe use of isotretinoin in women of reproductive age in the Netherlands. Furthermore, isotretinoin does not seem to be used in cases of severe acne only. Reserving isotretinoin prescribing to specialists may improve adherence to the PPP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Fig. 2

Similar content being viewed by others

References

  1. European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP). Summary information on a referral opinion following an arbitration pursuant to article 29 of directive 2001/83/EG, for isotretinoin/lurantal/trivane/rexidal/scheritonin [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/referral/isotretinoin/281103en1pdf [Accessed 2009 Apr 20]

  2. Brelsford M, Beute TC. Preventing and managing the side effects of isotretinoin. Semin Cutan Med Surg 2008; 27(3): 197–206

    Article  PubMed  CAS  Google Scholar 

  3. Azoulay L, Oraichi D, Bérard A. Patterns and utilization of isotretinoin for acne from 1984 to 2003: is there need for concern? Eur J Clin Pharmacol 2006; 62: 667–74

    Article  PubMed  CAS  Google Scholar 

  4. Bérard A, Azoulay L, Koren G, et al. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol 2007; 63(2): 196–205

    Article  PubMed  Google Scholar 

  5. Stern R, Rosa F, Baum C. Isotretinoin and pregnancy. J Am Acad Dermatol 1984; 10(5): 851–4

    Article  PubMed  CAS  Google Scholar 

  6. Dai W, LaBraico J, Stern R. Epidemiology of isotretinoin exposure during pregnancy. J Am Acad Dermatol 1992; 26(4): 599–606

    Article  PubMed  CAS  Google Scholar 

  7. Sladden MJ, Harman KE. What is the chance of a normal pregnancy in a woman whose fetus has been exposed to isotretinoin? Arch Dermatol 2007; 143(9): 1187–8

    Article  PubMed  Google Scholar 

  8. Lammer E, Flannery D, Barr M. Does isotretinoin cause limb reduction defects? Lancet 1985; II(8450): 328

    Article  Google Scholar 

  9. Atanackovic G, Koren G. Young women taking isotretinoin still conceive: role of physicians in preventing disaster. Can Fam Physician 1999; 45: 289–92

    PubMed  CAS  Google Scholar 

  10. Cragan J, Friedman J, Holmes L, et al. Ensuring the safe and effective use of medications during pregnancy: planning 326 and prevention through preconception care. Matern Child Health J 2006; 10 (5 Suppl.): S129–35

    Article  PubMed  Google Scholar 

  11. Mitchell AA, Van Bennekom CM, Louik C. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 1995; 333(2): 101–6

    Article  PubMed  CAS  Google Scholar 

  12. Stern RS. Isotretinoin prescribing: finding a balance between benefit and risk. Pharmacoepidemiol Drug Saf 2005; 14: 611–3

    Article  PubMed  Google Scholar 

  13. Schonfeld T, Amoura N, Kartochvil C. iPLEDGE allegiance to the pill: evaluation of year 1 of a birth defect prevention and monitoring system. J Law Med Ethics 2009; 37(1): 104–17

    Article  PubMed  Google Scholar 

  14. European Medicines Agency, Committee for Proprietary Medicinal Products (CPMP). Summary information on a referral opinion following an arbitration pursant to article 29 of directive 2001/83/EC, for isotretinoin/lurantal/ trivane/rexidal/scheritonin [online]. Available from URL: http://www.ema.europa.eu/pdfs/human/referral/isotretinoin/281103en1.pdf [Accessed 2010 Feb 19]

  15. Merck. The Merck manual: isotretinoin drug information [online]. Available from URL: http://www.merck.com/mmpe/lexicomp/isotretinoin.html#N1065CB [Accessed 2010 Feb 19]

  16. Sandoz. Isotreinoine sandoz 10/20 mg [online]. Available from URL: http://www.sandoz.nl/assets/content/nl/Assortiment/Isotretinoine-Richtlijnen&waarschuwingen_arts.pdf [Accessed 2010 Feb 19]

  17. Ratiofarm product information. Zwangerschaps preventie programma isotretinoine actavis [online]. Available from URL: http://db.cbg-meb.nl/Bijsluiters/h29163.pdf [Accessed 2010 Feb 19]

  18. Roche product information. Pregnancy prevention program: a risk management program to reduce pregnancies during accutane treatment [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3639b1c_06.pdf [Accessed 2010 Feb 19]

  19. Smeets JG, Grooten SJ, Bruinsma M, et al. NHG-standard acne. Huisarts Wet 2007; 50: 259–68

    Google Scholar 

  20. College ter Beoordeling van Geneesmiddelen. IB1 tekst [online]. Available from URL: http://www.cbg-meb.nl/CBG/nl/humane-geneesmiddelen/geneesmiddeleninformatiebank/default.htm [Accessed 2010 Feb 19]

  21. Drug Information Center. Compendium of drug information. The Hague: The Royal Dutch Association of Pharmacists (KNMP), 2008: 312

  22. Commissie Farmaceutische Hulp. Isotretinoïne: waarschu-wingen en voorzorgen. Amstelveen: Farmacotherapeutisch kompas. College voor Zorgverzekeringen, 2007

  23. Mantel-Teeuwisse AK, Straus SMJM, Lekkerkerker JFF, et al. Community pharmacists’ adherence to the isotretinoin pregnancy prevention program in the Netherlands. Drug Saf 2007; 30(10): 919–90

    Article  Google Scholar 

  24. World Health Organization Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. Oslo: WHO, 2004

    Google Scholar 

  25. Dutch Foundation of Pharmaceutical Statistics (SFK). Rem op groei apotheken door sluitingen [online]. Available from URL:http://www.sfk.nl/publicaties/farmacie_in_cijfers/2009/2009-08.html [Accessed 2010 Feb 19]

  26. Garcia-Bournissen F, Tsur L, Goldstein LH, et al. Fetal exposure to isotretinoin: an international problem. Reprod Toxicol 2008; 25(1): 124–8

    Article  PubMed  CAS  Google Scholar 

  27. Bensouda-Grimaldi L, Jonville-Bera AP, Mouret E, et al. Isotretinoin: compliance with recommendations in child-bearing women. Ann Dermatol Venereol 2005; 132(5): 415–23

    Article  PubMed  CAS  Google Scholar 

  28. Cheetham TC, Wagner RA, Chiu G, et al. A risk management program aimed at preventing fetal exposure to isotretinoin: retrospective cohort study. J Am Acad Dermatol 2006; 55(3): 442–8

    Article  PubMed  Google Scholar 

  29. Nava-Ocampo A, Koren G. Human teratogens and evidence-based teratogen risk counseling: the motherisk approach. Clin Obstet Gynecol 2007; 50(1): 123–31

    Article  PubMed  Google Scholar 

  30. NationMaster. Health statistics: age of women at first childbirth (most recent) by country [online]. Available from URL: http://www.nationmaster.com/graph/hea_age_of_wom_at_fir_chi-health-age-women-first-childbirth [Accessed 2010 Feb 19]

  31. Wikipedia. Vasectomie [online]. Available from URL: http://nl.wikipediaorg/wiki/Vasectomie [Accessed 2009 Sep 14]

  32. GIPdatabank: informatie over genees — en hulpmiddelen [online]. Available from URL: http://www.gipdatabank.nl/ [Accessed 2010 Feb 19]

  33. Robertson J, Polifka JE, Avner M, et al. A survey of pregnant women using isotretinoin. Birth Defects Res A Clin Mol Teratol 2005; 73(11): 881–7

    Article  PubMed  CAS  Google Scholar 

  34. Brinker A, Kornegay C, Nourjah P. Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the accutane SMART program. Arch Dermatol 2005; 141(5): 563–9

    Article  PubMed  Google Scholar 

  35. iPLEDGE: committed to pregnancy prevention [online]. Available from URL: http://www.ipledgeprogram.com [Accessed 2009 Feb 13]

Download references

Acknowledgement

No sources of funding were used to assist in the preparation of this study. The authors have no conflicts of interest to declare that are directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. Department of Epidemiology, Erasmus Medical Center, PO Box 2040, 3000 CA, Rotterdam, the Netherlands

    Martina Teichert, Loes E. Visser &  Bruno H.Ch. Stricker

  2. Scientific Institute of Dutch Pharmacists, The Hague, the Netherlands

    Martina Teichert & Peter A. G. M. Smet

  3. Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, the Netherlands

    Loes E. Visser

  4. Dutch Foundation of Pharmaceutical Statistics, The Hague, the Netherlands

    Mark Dufour

  5. Drug Safety Unit, Inspectorate for Health Care, The Hague, the Netherlands

    Eline Rodenburg &  Bruno H.Ch. Stricker

  6. Department of Medical Informatics, Erasmus Medical Center, Rotterdam, the Netherlands

    Sabine M. J. M. Straus &  Bruno H.Ch. Stricker

  7. Dutch Medicines Evaluation Board, The Hague, the Netherlands

    Sabine M. J. M. Straus

  8. Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands

    Peter A. G. M. Smet

  9. Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands

    Bruno H.Ch. Stricker

Authors
  1. Martina Teichert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Loes E. Visser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark Dufour
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eline Rodenburg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sabine M. J. M. Straus
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Peter A. G. M. Smet
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bruno H.Ch. Stricker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bruno H.Ch. Stricker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Teichert, M., Visser, L.E., Dufour, M. et al. Isotretinoin Use and Compliance with the Dutch Pregnancy Prevention Programme. Drug-Safety 33, 315–326 (2010). https://doi.org/10.2165/11319190-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11319190-000000000-00000

Keywords

Search

Navigation